Estriol

Estriol (Oestriol), an orally active estrogen, is a ERα and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects[1][2][3].

Product Specifications

CAS Number

[50-27-1]

Product Name Alternative

Oestriol

UNSPSC

12352005

Hazard Statement

H351, H360, H362

Target

Endogenous Metabolite; Estrogen Receptor/ERR

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Estriol.html

Purity

98.47

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

C[C@@]1([C@H]2O)[C@](C[C@H]2O)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1

Molecular Formula

C18H24O3

Molecular Weight

288.39

Precautions

H351, H360, H362

References & Citations

[1]Rosamaria Lappano, et al. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2010 May 14;320 (1-2) :162-70.|[2]Rainer Girgert, et al. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol. BMC Cancer. 2014 Dec 11:14:935. |[3]Aakifa Ahmad, et al. Proconvulsant effects of estriol, the third estrogen, in the mouse PTZ-kindling model. Neurol Sci. 2014 Oct;35 (10) :1561-6.